Long-term Safety of Tozorakimab in COPD Patients
Part of Lungs & breathing clinical trials.
This study follows patients who previously took part in a tozorakimab trial to see how safe the drug is over time. Tozorakimab is an antibody treatment designed to reduce flare-ups (exacerbations) in people with COPD, a chronic lung disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have participated in an earlier tozorakimab study for COPD
- You live in France and are enrolled in French Social Security
- You are willing and able to use contraception as previously agreed
- You have COPD as your main lung condition (no other serious lung diseases)
- You have not received recent immunosuppressive medications or live vaccines (within specific timeframes)
- You are able to follow all study visits, procedures, and restrictions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how much tocilizumab (an injected biologic) stays in your blood. It aims to understand why some patients respond better and to help guide dosing. If you have rheumatoid arthritis that's mild or in remission and are already scheduled for this treatment, you might be able to join.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This Phase 3 study tests tozorakimab to see if it helps people hospitalized with a viral lung infection that is causing low oxygen levels. You might qualify if you still need supplemental oxygen when the study starts.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
This study tests an experimental medication for chronic obstructive pulmonary disease (COPD) in two parts: first in healthy volunteers, then in people with COPD. It aims to see if the drug is safe and how well it works.
This study continues from an earlier trial to see if the experimental medicine tilrekimig remains safe and works well over a longer period for people with moderate-to-severe COPD. If you took part in the previous study, you might be able to join this one.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.